glutathione pathway to triple negative cancer GPX4 in triple-negative breast cancer: A key regulator of ferroptosis and therapeutic target Ferroptosis heterogeneity in triple-negative breast
Ferroptosis heterogeneity in triple negative breast cancer reveals an innovative immunotherapy combination strategy ScienceDirect Recent advances in targeted strategies for triple negative breast cancer Journal of Hematology & Oncology Springer Nature Link Excessive glutathione intake contributes to chemotherapy resistance in breast cancer: a propensity score matching analysis PMC GSTP1 Is a Driver of Triple Negative Breast Cancer Cell Metabolism and Pathogenicity ScienceDirect Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis augment to surmount triple negative breast cancer ScienceDirect
Pay in 4 interest-free payments of $6.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




